UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 19, 2019

 

GENEREX BIOTECHNOLOGY CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware   000-29169   98-0178636

(State or other jurisdiction of

incorporation)

  (Commission File Number)   (I.R.S Employer Identification No.)

 

10102 USA Today Way, Miramar, Florida   33025
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (416) 364-2551

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

  1  

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 19, 2019, Omar Gzouli tendered his resignation from the board of directors of Generex Biotechnology Corporation. Mr. Gzouli indicated that due to his current work schedule, he would be unable to give the proper time in to his service as a Generex board member .Mr. Gzouli has been reviewed the foregoing 8-K and agrees with the statements contained in this filing pertaining to the reason for his resignation.

 

  2  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    GENEREX BIOTECHNOLOGY CORPORATION.
   
Date: November 26, 2019   /s/ Joseph Moscato
    Joseph Moscato
    President and CEO

 

  3  

 

Generex Biotechnology (QB) (USOTC:GNBT)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Generex Biotechnology (QB) Charts.
Generex Biotechnology (QB) (USOTC:GNBT)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Generex Biotechnology (QB) Charts.